SpyGlass Pharma
Update in progressSGP (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
SpyGlass Pharma, Inc. is a biopharmaceutical company focused on treatments and drug delivery for chronic eye conditions. It is developing the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which places drug pads on an intraocular lens to be implanted during cataract surgery and help reduce elevated intraocular pressure. The company also works on a non-IOL, ring-shaped, sustained-release bimatoprost implant. Formerly SpyGlass Ophthalmics, it changed its name in 2021, was incorporated in 2019, and is based in Aliso Viejo, California.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!